先天性肾上腺皮质增生症的诊断治疗
Diagnosis and Treatment of Congenital Adrenal Cortex Hyperplasia
DOI: 10.12677/MD.2014.44009, PDF, HTML, 下载: 2,818  浏览: 9,425 
作者: 胡 啸, 张星星：中南大学湘雅二医院，长沙
关键词: 先天性肾上腺皮质增生症；诊断；治疗；Congenital Adrenal Hyperplasia； Diagnosis； Treatment
摘要: 先天性肾上腺皮质增生症是一组因为酶缺陷致肾上腺皮质增生的遗传病。本文就其病因、临床表现、诊断、治疗及监测指标等进行简单总结，以提高临床医师对此疾病的认识，减少漏诊误诊，改善预后。
Abstract: Congenital adrenal hyperplasia is a set of genetic disorders of adrenal cortex hyperplasia caused by enzyme defect. This paper summarized the etiology, clinical manifestation, diagnosis, treatment and monitoring indicators of it, in order to improve the clinical physicians’ awareness of the disease, reduce misdiagnosis, and improve the prognosis.
文章引用：胡啸, 张星星. 先天性肾上腺皮质增生症的诊断治疗[J]. 医学诊断, 2014, 4(4): 49-54. http://dx.doi.org/10.12677/MD.2014.44009

参考文献

[1] Gleen, H.K., Wiley, V., Wilcken, B., et al. (2008) Tow-year pilot study of newbom screening for congenital adrenal hyperplasia in New South Wales compared with nationwide case surveillance in Australia. Journal of Paediatrics and Child Health, 44, 554-559.
[2] Grunieiro-Papendieck, L., Chiesa, A., Mendez, V., et al. (2008) Neonatal screening for congenital adrenal hyperplasia: Experience and results in Argentina. Journal of Pediatric Endocrinology & Metabolism, 21, 71-78.
[3] 苗静琨, 万科星, 张娟, 等 (2010) 中华医学会第十五次全国儿科学术大会论文汇编. 重庆地区开展新生儿CAH和G6PD筛查的初步报告, 285-286.
[4] 张瑾, 孙亦骏, 黄美莲, 等 (2004) 南京市新生儿PKU、CH及CAH筛查结果分析. 南京医科大学学报, 24, 92-93.
[5] Behrman, R.E., et al. (2000) Nelson textbook of pediatrics. 16th Edition, Saunders Company, Philadelphia, 1729-1736.
[6] Huang, N., Agrawal, V., Giacomini, K.M., et al. (2008) Genetics of P450 oxidoreductase: Sequence variation in 842 individuals of four ethnicities and ac-tivities of 15 missense mutation. Proceedings of the National Academy of Sciences of the United States of America, 105, 1733-1738.
[7] Matteson, K.J., Picado-Leonard, J., Chung, B.C., et al. (1986) Assignment of the gene for adrenal P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase) to human chromosome 10. The Journal of Clinical Endocrinology & Metabolism, 63, 789-791.
[8] Lane, D.E. (2006) Polycysticovary syndrome and its differential diagnosis. Obstetrical & Gynecological Survey, 61, 125-135.
[9] Cavarzere, P., Camilot, M., Teofoli, F., et al. (2005) Neonatal screening for Congenital adrenal hyperplasia in North- Eastern Italy: A report three years in to the program. Hormone Research, 63, 180-186.
[10] Nimkarn, S. and New, M.I. (2009) Prenatal diagnosis and treatment of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Molecular and Cellular Endocrinology, 300, 192-196.
[11] 马定远, 孙云, 陈玉林, 杨冰, 成建, 黄美莲, 等 (2013) 21羟化酶缺陷症基因诊断方法的建立及应用. 中华医学遗传学杂志, 1, 49-53.
[12] White, P.C. (2009) Neonatal screening for congenital abrenal hyperplasia. Nature Reviews Endocrinology, 5, 490-498.
[13] Balsamo, A., Baldazzi, L., Menabo, S. and Cicognani, A. (2010) Impact of molecular genetics on congenital abrenal hyperplasia management. Sexual Development, 4, 233-248.
[14] Nimkarn, S. and New, M.I. (2009) Prenatal diagnosis and treatment of congenital abrenal byperplasia due to 21-hyperplasia deficiency. Molecular and Cellular Endocrinology, 300, 192-196.
[15] Cardoso, C.B., Fonseca, A.A., De Oliveira, M.F., et al. (2005) Congenital adrenal hyperplasia newborn screening: Riode Janeiro experience. Arquivos Brasileiros de Endocrinologia & Metabologia, 49, 112-119.
[16] Kim, Y.M., Kang, M.J., Choi, J.-H., et al. (2014) A review of the literature on common CYP17A1 mutations in adults with 17-hydroxylase/17, 20-lyase deficiency, a case series of such mutations among Koreans and functional characteristics of a novel mutation. Metabolism Clinical and Experimental, 63, 42-49.
[17] 罗小平, 祝婕 (2006) 先天性肾上腺皮质增生症的诊断和治疗. 实用儿科临床杂志, 8, 5l0-512.
[18] Lajic, S., Nordenström, A. and Hirvikoski, T. (2011) Long-term outcome of prenatal dexamethasone treatment of 21-hydroxylase deficiency. Pediatric Adrenal Diseases, 20, 96-105.
[19] Matthews, D. and Cheetham, T. (2013) What is the best approach to the teenage patient presenting with nonclassical congenital adrenal hyperplasia: Should we always treat with glucocorticoids. Clinical Endocrinology, 78, 338-341.
[20] Joint LWPSE/ESPE CAH Working Group (2002) Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. Journal of Clinical Endocrinology & Metabolism, 87, 4048-4053.
[21] Nguyen-An, T.T., Brown, J.J. and Warne, G.L. (2006) Growth in congenital hyperplasia. Indian Journal of Pediatrics, 73, 89-94.
[22] Charmandari, E., Johnston, A., Honour, J.W., et al. (2002) Treatment with flutamide decreases cortisol clearance: Implications for therapy in congenital adrenal hyperplasia. Journal of Pediatric Endocrinology and Metabolism, 15, 435- 439.
[23] Forest, M.G. (2004) Recent advances in the diagnosis and man-agement of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Human Reproduction Update, 10, 469-485.
[24] Meyer-Bahlburg, H.F. (2011) Brain development and cognitive, psychosocial, and psychiatric functioning in classical 21-hydroxylase deficiency. Pediatric Adrenal Diseases, 20, 88-95.
[25] Charmandari, E., Chrousos, G.P. and Merke, D.P. (2005) Adrenocorticotropin hypersecretion and pituitary microadenoma following bilateral adrenalectomy in a patient with classic 21-hydroxylase deficiency. Journal of Pediatric Endocrinology and Metabolism, 18, 97-101.
[26] Lin-Su, A. and New, M.I. (2007) Effects of adrenal steroids on the bone metabolism of children with congenital adrenal hyperplasia. Annals of the New York Academy of Sciences, 1117, 345-351.
[27] Reisch, N., Arlt, W. and Krone, N. (2011) Health problems in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Hormone Research in Paediatrics, 76, 73-85.
[28] 肖慧文, 马华梅 (2011) 先天性肾上腺皮质增生症21羟化酶缺乏患者的生长与最终身高影响因素. 国际儿科学杂志, 3, 210-215.
[29] Karen, J., Loechner, S.P., et al. (2010) Decreased bone mineral density and vertebral compression fractures in a young adult male with 21-hydroxylase deficiency Congenital adrenal hyperplasia (CAH): Is CAH an unrecognized population at risk for Glucocorticoid-induced osteoporosis. Journal of Pediatric Endocrinology & Metabolism, 23, 179-187.